Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex-related outcomes from DETO2X-AMI.
Alfredsson J, James SK, Erlinge D, Herlitz J, Fröbert O, Dworeck C, Redfors B, Arefalk G, Östlund O, Jernberg T, Mars K, Haaga U, Lindahl B, Swahn E, Lawesson SS, Hofmann R; DETO2X-SWEDEHEART Investigators. Alfredsson J, et al. Among authors: erlinge d. Am Heart J. 2021 Jul;237:13-24. doi: 10.1016/j.ahj.2021.03.001. Epub 2021 Mar 6. Am Heart J. 2021. PMID: 33689730 Free article. Clinical Trial.
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Wallentin L, et al. Among authors: erlinge d. Eur Heart J. 2008 Jan;29(1):21-30. doi: 10.1093/eurheartj/ehm545. Epub 2007 Nov 30. Eur Heart J. 2008. PMID: 18055486 Clinical Trial.
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Erlinge D, et al. J Am Coll Cardiol. 2008 Dec 9;52(24):1968-77. doi: 10.1016/j.jacc.2008.07.068. J Am Coll Cardiol. 2008. PMID: 19055987 Free article. Clinical Trial.
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A. Varenhorst C, et al. Among authors: erlinge d. Am Heart J. 2009 Mar;157(3):562.e1-9. doi: 10.1016/j.ahj.2008.11.021. Epub 2009 Feb 6. Am Heart J. 2009. PMID: 19249429 Clinical Trial.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Varenhorst C, et al. Among authors: erlinge d. Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157. Epub 2009 May 9. Eur Heart J. 2009. PMID: 19429918 Free PMC article. Clinical Trial.
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. James S, et al. Among authors: erlinge d. Eur Heart J. 2010 Dec;31(24):3006-16. doi: 10.1093/eurheartj/ehq325. Epub 2010 Aug 29. Eur Heart J. 2010. PMID: 20802246 Free PMC article. Clinical Trial.
520 results